China’s oncology drug developer InnoCare eyes up to $288m in HK IPO

Oncology therapy-focused InnoCare Pharma Limited is seeking up to HK$2.24 billion ($288 million) in an initial public offering (IPO) on the Hong Kong stock exchange (HKEX), per a company statement.